Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors
{{output}}
Objective: In peptide receptor radionuclide therapy (PRRT) using lutetium-177-labeled DOTA-Tyr3-octreotate ([177Lu] DOTATATE), isolation is required until the external dose rate at 1 m (EDR-1 m) from the body surface falls below ... ...
